<SEC-DOCUMENT>0001639691-18-000060.txt : 20180531
<SEC-HEADER>0001639691-18-000060.hdr.sgml : 20180531
<ACCEPTANCE-DATETIME>20180531114109
ACCESSION NUMBER:		0001639691-18-000060
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180531
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180531
DATE AS OF CHANGE:		20180531

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LivaNova PLC
		CENTRAL INDEX KEY:			0001639691
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				981268150
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37599
		FILM NUMBER:		18870568

	BUSINESS ADDRESS:	
		STREET 1:		20 EASTBOURNE TERRACE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W2 6LG
		BUSINESS PHONE:		4402033250662

	MAIL ADDRESS:	
		STREET 1:		20 EASTBOURNE TERRACE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W2 6LG

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sand Holdco Plc
		DATE OF NAME CHANGE:	20150420

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sand Holdco Ltd
		DATE OF NAME CHANGE:	20150415
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>livanovaform8-kamendno1.htm
<DESCRIPTION>8-K/A AMENDMENT NO. 1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCEBCA5862479CCC5327AB6B4199D2507"></a></div><div></div><div><br></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 8-K/A</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amendment No. 1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  May 31, 2018</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;"><img src="livanovaform8k_image1a01.jpg" alt="livanovaform8k_image1a01.jpg" style="height:54px;width:172px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LivaNova PLC</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">England and Wales</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-37599</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">98-1268150</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20 Eastbourne Terrace</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">London, W2 6LG</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">United Kingdom</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">+44 20 33250660</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s Telephone Number,&#160;Including Area Code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:67%;"></td><td style="width:30%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:67%;"></td><td style="width:30%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;"><hr></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sA72FE070BC6DB5D148D3B6B419B0B2A3"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPLANATORY NOTE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2018, LivaNova PLC (&#8220;LivaNova&#8221; or the &#8220;Company&#8221;) furnished a Current Report on Form 8-K (the &#8220;Original Form 8-K&#8221;).  This Amendment No. 1 to Current Report on Form 8-K/A (this &#8220;Amendment No. 1&#8221;) is being filed to include an omitted paragraph of text and highlighted information in the Original Form 8-K.  This Form 8-K/A includes the omitted information and restates in its entirety the Original Form 8-K.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESTATE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 30, 2018, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) published a tracking sheet to reconsider the National Coverage Determination (&#8220;NCD&#8221;) for LivaNova PLC&#8217;s (&#8220;LivaNova&#8221; or the &#8220;Company&#8221;) Vagus Nerve Stimulation Therapy</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;VNS Therapy&#8221;) System for Treatment-Resistant Depression (&#8220;TRD&#8221;). </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This decision by CMS follows LivaNova&#8217;s submission of a letter to CMS requesting a formal reconsideration of the NCD for VNS Therapy, NCD 160.18, specifically for TRD. Over the last decade, a significant body of new evidence has emerged showing that the addition of VNS Therapy is effective in reducing symptoms in patients with TRD.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The posting of the National Coverage Analysis (&#8220;NCA&#8221;) tracking sheet, https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=292&amp;TimeFrame=7&amp;DocType=All&amp;bc=AAAAIAAAQAAA&amp;, has opened the 30-day public comment period. Interested parties may comment on the NCA tracking sheet until June 29 as CMS brings greater attention to this important public health issue.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the 30-day comment period and up to six months later, CMS will release a Proposed Decision Memorandum. The proposed decision could result in any of the following possibilities or variations thereof: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CMS may confirm its NCD</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CMS may reverse its NCD</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CMS may remove the national non-coverage language from its NCD and allow its local Medicare Administrative Contractors (&#8220;MACs&#8221;) to make coverage decisions </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CMS may use a coverage with evidence development (&#8220;CED&#8221;) framework to expand coverage for patients with TRD while additional evidence is being collected</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once the Proposed Decision Memorandum is released, CMS will open another 30-day public comment period, after which, the agency will render a final decision on the NCD for VNS Therapy for TRD.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.71794871794873%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press Release issued by LivaNova PLC dated May 30, 2018</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.35897435897436%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex991pressreleasemay302018.htm"><font style="font-family:inherit;font-size:10pt;">Press Release issued by LivaNova PLC dated May 30, 2018</font></a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 2 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LivaNova PLC</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  May 31, 2018</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Catherine Moroz</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:  Catherine Moroz</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:    Company Secretary</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">- 3 -</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991pressreleasemay302018.htm
<DESCRIPTION>LIVANOVA PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBF10D18897128691906AB6B41A586593"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;-sec-extract:summary;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;font-size:11pt;font-weight:bold;-sec-extract:exhibit;" href="livanovaform8-kamendno1.htm"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT 99.1</font></a></div><div style="line-height:120%;text-align:left;"><img src="livnpressrelease_image1a01.jpg" alt="livnpressrelease_image1a01.jpg" style="height:62px;width:214px;"></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:Verdana,sans-serif;font-size:11pt;color:#ff5c39;">N</font><font style="font-family:Arial;font-size:11pt;color:#ff5c39;">EWS RELEASE</font></div><div style="line-height:120%;text-align:left;"><hr></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;color:#ff5c39;font-weight:bold;">LivaNova Comments on the U.S. Centers for Medicare &amp; Medicaid Services&#8217; Reconsideration of its National Coverage Determination for<br>VNS Therapy for Treatment-Resistant Depression</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">London, May 30, 2018 &#8211;</font><font style="font-family:Arial;font-size:11pt;">&#32;LivaNova PLC (NASDAQ:LIVN) (&#8220;LivaNova&#8221; or the &#8220;Company&#8221;), a market-leading medical technology company, today issued a statement in regard to the U.S. Centers for Medicare &amp; Medicaid Services&#8217; (&#8220;CMS&#8221;) publication of a tracking sheet to reconsider its National Coverage Determination (&#8220;NCD&#8221;) for the Company&#8217;s Vagus Nerve Stimulation Therapy</font><font style="font-family:Arial;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Arial;font-size:11pt;">&#32;(&#8220;VNS Therapy&#8221;) System for Treatment-Resistant Depression (&#8220;TRD&#8221;):</font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LivaNova has been engaged with CMS on this important issue and submitted a letter to CMS requesting a formal reconsideration of the NCD for VNS Therapy for patients with TRD. The Company is encouraged that CMS has taken this initial step, which may provide access to this important therapy for TRD that has been a Medicare non-covered indication for more than a decade.&#160;A change in the Medicare coverage status of VNS Therapy for TRD that ensures adequate patient access to this important therapy would be a positive outcome for patients and physicians. The posting of the National Coverage Analysis (&#8220;NCA&#8221;) tracking sheet</font><font style="font-family:Arial;font-size:11pt;color:#0000ff;">, </font><font style="font-family:Arial;font-size:11pt;">https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=292&amp;TimeFrame=7&amp;DocType=All&amp;bc=AAAAIAAAQAAA&amp;, has opened the 30-day public comment period. Interested parties may comment on the NCA tracking sheet until June 29 as CMS brings greater attention to this important public health issue. Over the last decade, a significant body of new evidence has emerged showing that the addition of VNS Therapy is effective in reducing symptoms in patients with TRD. We look forward to working with CMS as they consider a change in Medicare coverage.&#160; </font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#ff5c39;">About LivaNova</font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">LivaNova PLC&#160;is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova&#8217;s advanced </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in&#160;London,&#160;LivaNova&#160;has a presence in more than 100 countries worldwide. The Company currently employs more than 3,500 employees. LivaNova&#160;operates as two business franchises: Cardiac Surgery and Neuromodulation, with operating headquarters in Mirandola (Italy) and&#160;Houston&#160;(U.S.A.), respectively.</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">For more information, please visit </font><font style="font-family:Arial;font-size:11pt;">www.livanova.com</font><font style="font-family:Arial;font-size:11pt;font-weight:bold;">.</font></div><div style="line-height:180%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#ff5c39;">Safe Harbor Statement</font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova&#8217;s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," &#8220;could,&#8221; &#8220;seek,&#8221; &#8220;guidance,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221; "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to LivaNova and assumptions that LivaNova believes to be reasonable, but are inherently uncertain. As a result, LivaNova&#8217;s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance or actions that may be taken by LivaNova and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond LivaNova&#8217;s control. You should carefully consider the risks and uncertainties that affect LivaNova, including those described in the &#8220;Risk Factors&#8221; section of LivaNova&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission.</font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">All information in this news release is as of the date of its release. LivaNova does not undertake or assume any obligation to update publicly any of the forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">place undue reliance on any forward-looking statements, which are made only as of the date of this news release.</font></div><div style="line-height:180%;padding-bottom:16px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">LivaNova PLC Investor Relations and Media</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Karen King, </font><font style="font-family:Arial;font-size:11pt;">+1 (281) 228-7262</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Vice President, Investor Relations &amp; Corporate Communications</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">Deanna Wilke,</font><font style="font-family:Arial;font-size:11pt;">&#32;+1 (281) 727-2764</font></div><div style="line-height:138%;text-align:justify;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">Director, Corporate Communications &#8211; Products &amp; Therapies</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">corporate.communications@livanova.com</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:center;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">###</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>livanovaform8k_image1a01.jpg
<TEXT>
begin 644 livanovaform8k_image1a01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M:WD7FK$/NQMDA@/;H?QKTL-4<XZ]#TL-4<XZ]#U7X-_\D[TWZR_^C7KBQ/\
M%9Q8C^*SB-!\0_$R;7-/BU"#4Q:/<QK.7TQ54(6&[)\L8&,\UTSIT%%VM?U.
MB<*"B[6OZGI/CWPW'XH\.3V)"BX7]Y;N?X9!T_ ]#]:XZ53V<KG)2J>SE<\.
M^'/B.7PAXK O-T5M*WV>\1OX.<;B/53^F:]*M356&AZ-:G[6&A%\4B&\?:L5
M((,BD$=_D6GA_P"&AX?^&CUGQKJDNE?".*2V8I+/:00*P[!E ;_QW-<%**E6
MLSAI14JUF>=_!OPM9>(M;N9M3C\ZVL45O)/1W8G&?;@\=ZZ\34<(I1ZG7B:C
MA%)=3V+6_!>@:OIKV<NF6L(VD1R0Q*CQ'L5('Z=#7!&K.+NF>?&K.#NF> ^%
M;NX\->.;1E;#VUWY$H'\2[MK#\LUZ=1*I3?H>I42G39V7Q]T+[/J=IKD*82Z
M7R9B/[ZCY3^*\?\  :PPD]' Y\)/1Q.J^#GB*.Z\#O'=RA6TC<LC$](L%E/T
M R/^ UAB:?+4TZF.)ARU-.IY/I\,_CCQ^HD#?\3"Z+R>J1YR1^"C ^@KN;5&
MEZ':VJ-/T.S_ &@+]HY])TB+Y((XC.4'3.=J_D WYUSX..\CGPD=Y&Q\%O"6
MG+X=CUN\M8[B[NV;RS*@;RD5BO /<D$Y^E9XFI+FY5LB,34?-RK9$_QD\)Z=
M<>&;C5[6UC@O;(JY>) OF(6 (;'7KG/M[TL-4<9\O1DX:HU/EZ''_ #_ )'*
M\_[![_\ HR.NC%_ O4Z<7\"]22QU'X86%];WEO;:L)K>194)Y 93D<;O45+C
MB&K,EQQ#5F=G_P +B\+^E_\ ]^!_\56'U6H8?5:@J?&#PP[A0+[).!^Y'_Q5
M'U6H+ZK4./\ V@O^1BT[_KT_]G-;X/X6=&$^%G?_  >_Y)SI7_;;_P!'/7-B
M?XK.7$?Q6<=\?]!VO9:] G!_T:<CUY*'_P!"'Y5OA)[P.C"3W@>::EK-[JEC
MIEC<,7CT^(PP@=3EB?Y8'T45V1@H-M=3KC!0;:ZGTAX'T0>'O"UAIQ $J1[I
MO>1N6_4X^@%>15GSS<CR:D^>;9\^^)K.Y\+>.+E=FU[6[\^#/1EW;D/Y8_6O
M5IM5*9ZE-JI3/=='^(7AK4M-2Z?5;:T<KEX;B0(Z'N,'K^%>9*A.+M8\V5"<
M7:QXS\5/%%OXH\2":PR;.VC$,3$8+\DEL=LD_D!7HX>FZ<==ST,/3=..NYZ[
M\&_^2=Z;]9?_ $:]<&)_BLX<1_%9AZ3!\51JMF=2NH6LQ.GG@"WYCW#=T7/3
M/2M)/#V=EK\S23P]G9:_,].KC.,\1^.?A7[%J*:_9QX@NSLN !]V7'#?\" _
M,>]>CA:EUR,]'"U+KD9YE--).^^9V=L!<L><   ?D!7:DEL=B26Q]!^*]'FU
MOX416UJI>>.S@FC4=6*JI('N1FO)IS4*MV>53DH5;L\N^$_BZV\*ZU,-1#"R
MO$"2.H),9!RK8[CDY^M=V(I.I'3=';B*3J1TW1ZSK7Q+\,Z=ISW%OJ,5[-M)
MB@AR68]@?[OXUP1P]23M:QPQH3D[6L>*^"=.N?$OC>T7;N+W'VFX8#A5#;F/
M]/J17HU9*G39Z%5JG39[[X[T,>(?"M]IZKF9DWP^TB\K^?3Z&O+I3Y)IGF4I
M\DTSYPTO6;S2+34K2V8HFH0^1,#Q@;@?SQD?1C7KR@I--]#UI04FF^AZ9^S_
M *'S?ZY,G3_1H"?P+G_T$?G7'BY[0.3%SVB+^T%I,I.FZO&A,:@V\I'\/.Y?
M_9J,'+>(L)+>(_X.^.M+LM$&B:O<QV3V[LT,DIVHRL<D$] 02>OK2Q-&3ES1
M08FC)RYHD_Q>\=:5/X>ET;2+N*]GNF7S'A;<D: Y^\."20!@=L^U+#T9*7-)
M6L+#T9*7-)6L<[\ /^1RO/\ L'O_ .C(ZVQ?P+U-L7\"]38_X49_U,?_ ))?
M_;*S^N?W?Q,_KG]W\0_X49_U,?\ Y)?_ &RCZY_=_$/KG]W\1T?P.V2*W_"1
M9VD''V+_ .V4/&?W?Q$\7_=_$Z7X@_#S_A,=1MKO^U/L7D1>5M^S^9GDG.=P
M]:QHU_9)JQC1K^R35CH/!VA?\(UX<M-(^T_:OLV_][LV;MSLW3)Q]['6LJD^
M>3D9U)\\G(E\4:)#XBT&[TJX;RUN$PKXSL8'*MCO@@<4H3<)*2%";A)21P6@
M?!N'2]:L[^YUC[7';2B3R?LNS>1R.=Y[X[5U3Q3E%I*QTSQ3E%I(]0KB.,YO
MQMX*TSQ=;(+S=!=1 B*YC W*/0CN/;\L5K2JRI/0UI594GH><M\$-0%QM76;
M4PY^^8F#8_W>GZUU_7%;8Z_KBML;FH?!G3YM,LK6RU%K:> NTUPT&\SEMO;<
M-H&.!SU/UK..+DFVT9QQ4DVVCM?!N@_\(SX=MM)^T_:OLY<^;Y>S=N8MTR?7
MUKGJ3YY.1SU)\\G(Y73/ASK-EJ5K=2^-;^XC@F21H61\2 $$J?WAX.,=*VE7
M@TTH+^OD;2KP::Y%_7R/0ZY3E*.NZ5;:WI%UIMZN8;E"I]5/9A[@X(^E5&3@
MTT5&3@TT>7?\*,_ZF/\ \DO_ +97;]<_N_B=OUS^[^)ZOIMK]ATZUM-_F?9X
MDBW8QNV@#..W2N%N[N<+=W<X/QC\)M.UN[DOM+N/[-NI"6D39NB<^N.-I/MQ
M[5TTL3*"L]4=-/$R@K/4YBV^".HF8"ZU>UCB[F.-G;\CC^=;O&+HC9XQ=$>F
M^#_".E^$[-H=-1FEDQYL\G+R?X#V%<52K*H[LXZE651W9O5F9GE^O_!N'5-:
MN[^VUC[''<R&3R?LN_83R>=X[Y/2NV&*<8I-'9#%.,4FCO/"VB0^'-!M-*MW
M\Q;=<-)MV[V)RS8YQDD]ZY9S<Y.1S3FYR<BWJ5A:ZG8S65_"L]M,NUXVZ$?Y
M[U*;B[HE-Q=T>4:Q\$F-PSZ-JJK"QXBN4.5_X$.OY"NZ.,T]Y';'%Z>\B_H'
MP:M+2VNCJM\+FYFA>*+9'\D#,"-^"<L1VZ?X1/%-M<J)GBFVK(UOA_\ #?\
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3 !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>livnpressrelease_image1a01.jpg
<TEXT>
begin 644 livnpressrelease_image1a01.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "/ >T# 2(  A$! Q$!_\0
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M;K_OZW^-']OWQ_Y?;K_O\W^-?TR?\/ _V8_^BK?"3_P;VG_Q5!_X*!?LQ?\
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M_P!XI_XE^9_+[7T1_P $EO\ E))\&_\ L8X?Y-7SO7T1_P $EO\ E))\&_\
ML8X?Y-7[5F'^Z5/\+_(_8L=_NM3_  O\C^FB[MX[NVDBE19(Y%*NC#<K \$$
M>E?S"_\ !2K]EB3]CK]L_P ;>"XX6AT>*\-_HQ(X>QG_ 'D(![[ 3&3_ 'HV
MK^GZORP_X.:?V4#XJ^$_A7XO:;;;KSPM<?V+J[(O)LYVS"['T2;*_P#;Q[5^
M9\)8_P!AC?92^&>GSZ?Y?,_.>%<=[#&>REM/3Y]/\OF?BU7]"7_!O_\ M/\
M_"_?V"-*T*]N/.UOX<W#:!.&;YS; ;[5L?W1$WEC_KB:_GMK[^_X-UOVG/\
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M_13^RQ^T9H?[6/P"\,_$#P[(K:;XCLUG\K=E[64$K+"_^U'(K(?=?2OYUO\
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M9&;>,J+9VCZ]7_D%:'A?PEJOC?68=-T73=0U?4+@[8K6RMWN)I3_ +**"Q_
M5VW[)G[-&N_M?_M!^&_A[X=VQW_B"Y\M[AUW1V4"@O+.P_NH@9L=\ =2*_I*
M_8X_84^'?[#WPVM=!\$Z+!!<>4JW^K3(K:AJD@'+RRXSR<D(,*N< "OI<[X@
MIY>E&W--]-M.[9]%G6?4\ E&W--]/+NS^<+Q#^PU\:O"6AMJ>J?"+XFZ;IRJ
M7:YN?#%[%%&/5F:/"_CBO+G1HG965E93@@C!!K^O(C=7P/\ \%@O^"0WA?\
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MC>))+24@?<%Q;L0?S@ _$5^(]=?"5O[-C;N[_?\ Y6.SA6W]G1MW?YGZB?\
M!KM\.+76OVA/B9XHFC62XT'0;:P@8_\ +/[5.S,1[XML9]"1WK]L!P*_#G_@
MV-^,=GX._:K\:>#[N989/&6@I/9AFQYT]I*6V =SY4LK?2,U^XU?$\6*2S*7
M-M96]+?YW/C.*E)9C+F[*WI;_.X4C\J:6H[F=+:VDDD98XXU+,S' 4#DDFOF
MSYP_ET_X*(?#VU^%?[=/Q9T&QC6*QL?%%]]GC486*-Y6D11]%8#\*\:KU/\
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M/,*/+_,ONZ_@=N1J3Q]+E[K_ (/X'X3T445^U'[$?N/_ ,10'P<_Z$7XD_\
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M^](K]?1?\ ]//,UA@L.W?WWI%?KZ(^V-,TZ#2-.M[2UB2"VM8UBBC086-%
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M "<_^,U^W]%'^MF8_P R^Y!_K5F/\R^Y'XY_LZ?\&X?Q0^#'[07@7QA?>.O
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MQ./LN>*^"%[."?Q6YM_/R/5/B/X[NOAG^Q==:Y8G;?:?X:B>W;_GG(8556_
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M\$FOB)J'B?X/:WH5],]Q'X9OEBM68YV12*6\L>P96(]-V*\@^'WP*T_X^?\
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MRNZ.& 8@/O&Y2 <J/3GJ?V?$\8:U_P %%M"\1>,K6UL]2\0Z;/J"06\JNEO
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LZ?%&>W*^WR/LO[/AC<@I2S;$>QH1ITXQJTYMPG9Z0G1=GSQUNTEJKO8__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
